Fresenius Medical Care AG & Co. KGaA (FME) PT Set at €97.00 by Goldman Sachs Group, Inc. (The)

Goldman Sachs Group, Inc. (The) set a €97.00 ($115.48) price objective on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a research note released on Tuesday morning. The brokerage currently has a buy rating on the stock.

Other equities research analysts have also issued reports about the company. Oddo Securities set a €95.00 ($113.10) price objective on Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research note on Thursday, July 20th. Citigroup Inc. set a €92.00 ($109.52) price objective on Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research note on Friday, June 9th. Kepler Capital Markets set a €95.00 ($113.10) price objective on Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research note on Friday, June 9th. S&P Global set a €95.00 ($113.10) price objective on Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research note on Friday, June 9th. Finally, Berenberg Bank set a €95.00 ($113.10) price objective on Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research note on Friday, June 9th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have given a buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of €88.39 ($105.22).

Shares of Fresenius Medical Care AG & Co. KGaA (ETR:FME) opened at 81.69 on Tuesday. Fresenius Medical Care AG & Co. KGaA has a one year low of €70.82 and a one year high of €89.07. The company has a 50 day moving average price of €79.20 and a 200 day moving average price of €81.57. The company has a market cap of €25.07 billion and a P/E ratio of 21.06.

COPYRIGHT VIOLATION WARNING: “Fresenius Medical Care AG & Co. KGaA (FME) PT Set at €97.00 by Goldman Sachs Group, Inc. (The)” was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2017/09/16/fresenius-medical-care-ag-97-00-by-goldman-sachs-group-inc-the.html.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply